--- a
+++ b/README.md
@@ -0,0 +1,26 @@
+Title of Dataset: Cohesin\_mutations\_in\_acute\_myeloid\_leukemia\_data
+========================================================================
+
+Patients with acute myeloid leukemia (AML) from previously reported
+multicenter trials: AML96 \[NCT00180115\], AML2003 \[NCT00180102\],
+AML60+ \[NCT 00180167\], SORAML \[NCT00893373\] Pre-treatment peripheral
+blood or bone marrow aspirates were screened for genetic alterations
+using next-generation sequencing (NGS)
+
+Results: We identified distinct co-mutational patters for mutations of
+STAG2, which were associated with normal karyotypes (NK) and concomitant
+mutations in IDH2, RUNX1, BCOR, ASXL1, and SRSF2. Mutated RAD21 was
+associated with NK, mutated EZH2, KRAS, CBL, and NPM1. We found almost
+complete mutual exclusivity of genetic alterations of individual cohesin
+subunits. Conclusion: This mutual exclusivity may be the basis for
+therapeutic strategies via synthetic lethality in cohesin mutated AML.
+
+Data description: Cohesin mutation status is displayed differentiating
+between RAD21, STAG2, SMC3, SMC1A p.HGVS codes are used to denote
+specific alterations presence (1) or absence (0) of a feature is
+reported European Leukemia Net 2022 (ELN2022) risk stratification
+(Döhner et al., Blood 2022) was used.
+
+Further information on clinical trial protocols can be obtained from
+www.clinicaltrials.gov using the following identifiers: NCT00180115,
+NCT00180102, NCT 00180167, SORAML NCT00893373